<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28610">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734277</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN066AI</org_study_id>
    <nct_id>NCT02734277</nct_id>
  </id_info>
  <brief_title>Type 1 Diabetes Extension Study</brief_title>
  <acronym>T1DES</acronym>
  <official_title>Type 1 Diabetes Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To further our understanding of the immunologic mechanisms underlying maintenance and loss
      of beta cell function by evaluating the relationship between longitudinal changes in beta
      cell function and changes over time in biomarkers known to be associated with a response to
      immune modulating treatments which were used in prior clinical trials (Refer to
      ClinicalTrials.gov records NCT00129259 and NCT00965458).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes mellitus (T1DM) is an autoimmune disease. This means that the immune system
      (the part of the body that helps fight infections) mistakenly attacks the cells that produce
      insulin (beta cells in the pancreas). As beta cells are destroyed by the immune cells, the
      ability to produce insulin is decreased and diabetes develops. Insulin helps keep blood
      glucose levels normal.

      People with diabetes who have the ability to produce some of their own insulin (even though
      they still need to take insulin) may be able to achieve better glucose control than people
      who produce no insulin at all. Better glucose control has been shown to reduce the long-term
      complications of diabetes.

      Several Immune Tolerance Network (ITN) drug treatment studies have been completed and have
      shown that some participants with new onset T1DM had partial disease remissions with
      therapy. Prior participants in these trials, had measured insulin secretion, at six month
      intervals, up to two years after diabetes diagnosis. It is unclear, however, if any of the
      interventions have produced a continuing disease remission in patients. For persons who have
      completed drug treatment trials, longer term follow-up is important for continued evaluation
      for effect of therapy on insulin production.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of changes in beta cell function overtime measured by mixed-meal tolerance test (MMTT) -Stimulated mean 4-hour C-Peptide area under the curve (AUC)</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin use in units per kilogram body weight per day</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C Percentages</measure>
    <time_frame>Six months</time_frame>
    <description>The A1C blood test, also called the hemoglobin A1C test, HbA1c, or glycohemoglobin test, reflects average blood glucose levels for the past 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-reported major hypoglycemic events</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Detectable C-peptide by MMTT</arm_group_label>
    <description>This cohort includes participants with a detectable C-peptide by 4-hour mixed-meal tolerance test (MMTT) during their last study visit:
at week 104, in prior Immune Tolerance Network (ITN) studies ITN027AI (AbATE) or -045AI (T1DAL) -Reference ClinicalTrials.gov study IDs NCT00129259 and NCT00965458
in the ITN027AI (AbATE) follow-up study (NCT02067923) and
in this study, ITN066AI (T1DES).
Detectable C-peptide is defined as any value during a MMTT of &gt;/=0.15 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undetectable C-peptide by MMTT</arm_group_label>
    <description>This cohort includes participants with undetectable C-peptide by 4-hour mixed-meal tolerance test (MMTT):
during their last study visit at week 104, in prior Immune Tolerance Network (ITN) studies ITN027AI (AbATE) or -045AI (T1DAL) -Reference ClinicalTrials.gov study IDs NCT00129259 and NCT00965458
after two undetectable C-peptide results by MMTT in the current study, ITN066AI (T1DES).
Undetectable C-peptide is defined as any value during a MMTT of &lt;0.15 ng/mL.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood or urine tests as needed to follow-up on potential long term safety concerns with
           a particular therapeutic agent

        -  Blood and urine samples for additional studies related to your diabetes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in selected completed Immune Tolerance Network (ITN) new-onset Type 1
        Diabetes (T1D) studies with immunomodulatory agents.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior participation in protocol ITN027AI AbATE(NCT00129259) or protocol ITN045AI
             T1DAL(NCT00965458) studies

          -  Ability to sign informed consent/assent (as applicable for children)

        Exclusion Criteria:

          -  Any medical condition that in the opinion of the principal investigator would
             interfere with safe completion of the trial.

          -  Inability to comply with the study visit schedule and required assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda DiMeglio, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University Riley Hospital for Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>General Recruitment</last_name>
      <phone>844-813-8273</phone>
      <email>clinicalresearch@diabetes.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Cook</last_name>
      <phone>(415)-502-9621</phone>
      <email>Ashley.Cook@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Rink</last_name>
      <phone>203-737-4510</phone>
      <email>linda.rink@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mikhail Smolgovsky</last_name>
      <phone>203-785-6248</phone>
      <email>mikhail.smolgovsky@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milton Brown</last_name>
      <phone>404-727-5709</phone>
      <email>mbrow05@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Felner, MD, MSCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Spall</last_name>
      <phone>317-278-7034</phone>
      <email>malnicho@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Hufferd</last_name>
      <phone>317-278-0528</phone>
      <email>rhufferd@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Linda DiMeglio, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care Division of Pediatric Endocrinology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne Cabbage</last_name>
      <phone>319-356-4035</phone>
      <email>joanne-cabbage@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Eva Tsalikian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Beidelschies</last_name>
      <phone>816-760-5918</phone>
      <email>mkbeidelschies@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Dolan</last_name>
      <phone>(816) 760-8876</phone>
      <email>jldolan@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wayne Moore, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marli M Olson</last_name>
      <phone>206-342-6943</phone>
      <email>marli@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>https://www.immunetolerance.org/studies/t1d-extended-study-t1des</url>
    <description>ITN T1D Extended Study (T1DES) website</description>
  </link>
  <reference>
    <citation>Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team.. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.</citation>
    <PMID>23835333</PMID>
  </reference>
  <reference>
    <citation>Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.</citation>
    <PMID>26193635</PMID>
  </reference>
  <reference>
    <citation>Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team.. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.</citation>
    <PMID>24622414</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>April 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin</keyword>
  <keyword>Glucose Intolerance</keyword>
  <keyword>Prior ITN027AI Study Participants-NCT00129259</keyword>
  <keyword>Prior ITN045AI Study Participants-NCT00965458</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
